American Society of Hematology: Cilta-Cel Found Highly Effective in First Real-World Study
October 05, 2024
October 05, 2024
WASHINGTON, Oct. 5 (TNSres) -- The American Society of Hematology issued the following news release:
* * *
Study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma
* * *
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, pat . . .
* * *
Study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma
* * *
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, pat . . .